Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158


Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.

Iglesias-Gato D, Zheng S, Flanagan JN, Jiang L, Kittaka A, Sakaki T, Yamamoto K, Itoh T, Lebrasseur NK, Norstedt G, Chen TC.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):269-75. doi: 10.1016/j.jsbmb.2011.08.010. Epub 2011 Sep 3.


Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.

Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC.

Anticancer Res. 2009 Sep;29(9):3547-53. Erratum in: Anticancer Res. 2010 Mar;30(3):1033. Anticancer Res. 2010 Jan;30(1):277.


Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer.

Chen TC, Persons KS, Zheng S, Mathieu J, Holick MF, Lee YF, Bao B, Arai MA, Kittaka A.

J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):717-20. Epub 2007 Jan 4.


Human cytochrome P450-dependent differential metabolism among three 2α-substituted-1α,25-dihydroxyvitamin D(3) analogs.

Yasuda K, Ikushiro S, Kamakura M, Takano M, Saito N, Kittaka A, Chen TC, Ohta M, Sakaki T.

J Steroid Biochem Mol Biol. 2013 Jan;133:84-92. doi: 10.1016/j.jsbmb.2012.09.006. Epub 2012 Sep 13.


MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.

Chiang KC, Chen SC, Yeh CN, Pang JH, Shen SC, Hsu JT, Liu YY, Chen LW, Kuo SF, Takano M, Kittaka A, Sun CC, Juang HH, Chen TC.

J Steroid Biochem Mol Biol. 2014 Jan;139:54-60. doi: 10.1016/j.jsbmb.2013.10.005. Epub 2013 Oct 12.


19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells.

Chiang KC, Yeh CN, Chen HY, Lee JM, Juang HH, Chen MF, Takano M, Kittaka A, Chen TC.

Steroids. 2011 Dec 11;76(13):1513-9. doi: 10.1016/j.steroids.2011.08.006. Epub 2011 Aug 25.


Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.

Rhieu SY, Annalora AJ, LaPorta E, Welsh J, Itoh T, Yamamoto K, Sakaki T, Chen TC, Uskokovic MR, Reddy GS.

J Cell Biochem. 2014 Aug;115(8):1392-402. doi: 10.1002/jcb.24789.


Mechanism of the anti-proliferative action of 25-hydroxy-19-nor-vitamin D(3) in human prostate cells.

Munetsuna E, Nakabayashi S, Kawanami R, Yasuda K, Ohta M, Arai MA, Kittaka A, Chen TC, Kamakura M, Ikushiro S, Sakaki T.

J Mol Endocrinol. 2011 Aug 31;47(2):209-18. doi: 10.1530/JME-11-0008. Print 2011 Oct.


Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.

Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.

Recent Results Cancer Res. 2003;164:273-88.


Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.

Munetsuna E, Kawanami R, Nishikawa M, Ikeda S, Nakabayashi S, Yasuda K, Ohta M, Kamakura M, Ikushiro S, Sakaki T.

Mol Cell Endocrinol. 2014 Feb 15;382(2):960-70. doi: 10.1016/j.mce.2013.11.014. Epub 2013 Nov 27.


The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.

Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.

Clin Cancer Res. 2000 Mar;6(3):901-8.


MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.

Chiang KC, Yeh CN, Hsu JT, Chen LW, Kuo SF, Sun CC, Huang CC, Pang JH, Flanagan JN, Takano M, Kittaka A, Juang HH, Yang SW, Chen TC.

J Steroid Biochem Mol Biol. 2013 Nov;138:427-34. doi: 10.1016/j.jsbmb.2013.09.002. Epub 2013 Sep 14.


Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Kittaka A, Yoshida A, Chiang KC, Takano M, Sawada D, Sakaki T, Chen TC.

Future Med Chem. 2012 Oct;4(16):2049-65. doi: 10.4155/fmc.12.130. Review.


CYP24A1 as a potential target for cancer therapy.

Sakaki T, Yasuda K, Kittaka A, Yamamoto K, Chen TC.

Anticancer Agents Med Chem. 2014 Jan;14(1):97-108. Review.


Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.

Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R.

Clin Cancer Res. 2004 Dec 1;10(23):8018-27.


Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1.

Urushino N, Nakabayashi S, Arai MA, Kittaka A, Chen TC, Yamamoto K, Hayashi K, Kato S, Ohta M, Kamakura M, Ikushiro S, Sakaki T.

Drug Metab Dispos. 2007 Sep;35(9):1482-8. Epub 2007 Jun 6.


Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

Skowronski RJ, Peehl DM, Feldman D.

Endocrinology. 1995 Jan;136(1):20-6.


Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

Chow EC, Quach HP, Vieth R, Pang KS.

Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E977-89. doi: 10.1152/ajpendo.00489.2012. Epub 2013 Mar 12.


Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.

Chiang KC, Yeh CN, Hsu JT, Yeh TS, Jan YY, Wu CT, Chen HY, Jwo SC, Takano M, Kittaka A, Juang HH, Chen TC.

Cell Cycle. 2013 Apr 15;12(8):1316-25. doi: 10.4161/cc.24445. Epub 2013 Apr 2.


Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1.

Sawada N, Kusudo T, Sakaki T, Hatakeyama S, Hanada M, Abe D, Kamao M, Okano T, Ohta M, Inouye K.

Biochemistry. 2004 Apr 20;43(15):4530-7.


Supplemental Content

Support Center